Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

PBGENE-HBV cccDNA elimination data fuels DTIL upside into 2028 milestones

Aug 6, 2026, 7:07 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Material positive clinical data for PBGENE-HBV (cccDNA elimination, durable pgRNA loss) and progress in PBGENE-DMD plus capital runway improvements are likely to lift DTIL valuation; historical biotech catalysts around key trial updates often drive outsized moves, especially when data support root-cause cures.

AI summary

What happened, with direct paths to the underlying reporting

Precision BioSciences reports Q2 2026 results with first clinical biopsy evidence that PBGENE-HBV eradicates cccDNA, including a 1-log reduction and durable pgRNA loss in evaluable patients. The company also notes ongoing DMD recruitment and expects year-end updates, backed by a $112.4 million cash position and a runway through 2028 to reach multiple data milestones.

First biopsy shows direct cccDNA elimination; 1-log reduction, <1% remaining.
EASL data: pgRNA loss observed in 100% evaluable patients.
DMD trial sites actively recruiting; FUNCTION-DMD progressing toward safety data.
Year-end 2026 updates; PBGENE-HBV and PBGENE-DMD milestones through 2028.
Cash balance $112.4M as of 6/30/2026; runway through 2028.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

PBGENE-HBV cccDNA elimination data fuels DTIL upside into 2028 milestones

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst